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Primary immunodeficiency diseases (PID) area heterogeneous group of disorders caused
by genetic defects of the immune system, whichmanifest clinically as recurrent infections,
autoimmune diseases or malignancies. Early detection of PID remains a challenge,
particularly in older children with milder and less specific symptoms. This study aimed
to assess TREC and KREC diagnostic ability in PID. Data from children assessed by
clinical immunologists at Speransky Children’s Hospital, Moscow, Russia with suspected
immunodeficiencies were analyzed between May 2013 and August 2016. Peripheral
blood samples were sent for TREC/KREC, flow cytometry (CD3, CD4, CD8 and
CD19), IgA and IgG analysis. A total of 434 children [189 healthy, 97 with group I
and II PID (combined T and B cell immunodeficiencies & well-defined syndromes with
immunodeficiency) and 148 group III PID (predominantly antibody deficiencies)] were
included. Area under the curve (AUC) for TREC in PID groups I and II diagnosis reached
0.82 (CI = 0.75–0.90), with best model providing sensitivity of 65% and specificity of
92%. Neither TREC, nor KREC had added value in PID group III diagnosis. In this study,
the predictive value of TREC and KREC in PID diagnosis was examined. We found that
the TREC had some diagnostic utility for groups I and II PID. Possibly, addition of TREC
measurements to existing clinical diagnostic algorithms may improve their predictive
value. Further investigations on a larger cohort are needed to evaluate TREC/KREC
abilities to be used as diagnostic tools on a wider scale.
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HIGHLIGHTS
- What is already known about this topic?
Assessment of TREC levels is actively used in the screening of
severe combined immunodeficiency disorders (SCID).
- What does this article add to our knowledge?
This study shows that TRECmay have a place not just in SCID
screening but in the diagnosis of PID.
- How does this study impact current management guidelines?
Evidence suggests that TREC may be a good addition to
already existing diagnostic methods in groups I and II
PID diagnosis. It may be particularly useful in less affluent
environments with lack of access to flow cytometry.
INTRODUCTION
Primary immunodeficiency diseases (PID) are a heterogeneous
group of disorders caused by genetic defects of the immune
system, which manifest clinically as recurrent infections,
autoimmune diseases or malignancies. The most severe forms of
PID, severe combined immune deficiency (SCID) is intensively
studied and has been found to be associated with fatal
consequences in the first 2 years of life (1, 2).
Most forms of SCID can be detected by measuring the levels
of T-cell recombination excision circles (TREC) in dried blood
spots using real-time polymerase chain reaction (PCR) (3), while
kappa-deleting recombination excision circles (KREC) are used
to screen for agammaglobulinemia (4). TREC is a by-product
of the T-cell receptor gene recombination, and KREC is a by-
product of the B-cell receptor recombination. Low levels of these
molecules in T- and B-cells in peripheral blood were shown to
be associated with T- and/or B-cell lymphopenia (4). The best
possible outcome for patients with SCID can be achieved by
timely hematopoietic stem cell transplantation or gene therapy
before the development of infectious complications (5, 6),
while early diagnosis is associated with a significant increase in
treatment effectiveness (5). In patients with agammaglobunemia,
the best outcome is achieved by initiating replacement therapy
using intravenous or subcutaneous immunoglobulins.
PID influence child health-related quality of life, limiting
physical, emotional, social and school functioning (7). Therefore,
early detection of not only SCID but all PID patients is vital
to improve the chances of appropriate management, in order
to significantly reduce potential complications and improve life
quality (6, 8).
At present, early detection of PID remains a challenge. This is
particularly true in older children and in adults, potentially due
to milder and less specific symptoms, a low level of awareness
of PID amongst clinicians, as well as unavailability of necessary
Abbreviations: AUC, Area under receiver operating characteristic curve; CD,
cluster of differentiation; CVID, Common Variable Immunodeficiency; DNA,
Deoxyribonucleic acid; ICD-10, International Classification of Diseases, 10th
Revision; Ig, immunoglobulin; IUIS, International Union of Immunological
Societies; KREC, kappa-deleting element recombination circle; PCR, polymerase
chain reaction; PID, Primary immunodeficiency diseases; ROC, Receiver
Operating Curve; SCID, Severe Combined Immune Deficiency; TREC, T-cell
recombination excision circles.
diagnostic devices such as flow cytometry in hospital laboratories
(9, 10). In some countries flow cytometry is not readily available
and TREC/KREC analysis may represent a feasible alternative. It
is therefore imperative to not only allow diagnosis of patients
in low-resource facilities but also develop more cost-effective
alternatives. Many studies showed that dried blood spots are
robust (11) and useful as a potential alternative sample source for
clinical purposes, epidemiological studies, and biobanking (12).
Flow cytometry is a more commonly used but more expensive
diagnostic technique for PID detection, when compared with
PCR (13). It requires a significant amount of training in highly
specialized tertiary centers and therefore cannot be used as a
screening tool.
Potential applications of TREC/KREC analysis were
highlighted in the reviews by van Zelm and co-authors
(14, 15). These included support therapy monitoring, patient
classification and newborn screening for PID. Apart from
apparent clinical benefits, assessment of B- and T- cell neogenesis
in PID patients following stem cell transplantation (16) and
KREC assessment in patients presenting with abnormalities in
B-cell subsets to explain B-cell compartment aberrancies (17)
may improve current state of knowledge.
This pilot study aims to assess diagnostic accuracy of
TREC and KREC in children from 0 to 18 years of age with
suspected PID.
METHODS
Study Setting, Eligibility Criteria, and Ethics
In this prospective study, we recruited all children referred by
primary care physicians (polyclinic pediatricians) to a tertiary
level center (Moscow City Pediatric Hospital #9 named after
Speransky, Moscow, Russia) with suspected immunodeficiencies
and assessed by board-certified clinical immunologists between
May 2013 and August 2016. The investigations and sample
collection were conducted following ethical approval by the
Speransky Children’s Hospital Ethics Committee. Parental
written consent was obtained for all participants as part of routine
procedure at Speransky Children’s Hospital. Parents/guardians
were informed of the procedures in lay terms. The study design
has been described in detail elsewhere (18).
Outcome Definition
The primary outcome of interest in this study was PID.
We considered that a child has a PID if he or she had
PID diagnosed by a physician. The diagnosis of different
groups of PID was based on IUIS Phenotypic Classification
for Primary Immunodeficiencies (19): group I was defined as
immunodeficiencies affecting cellular and humoral immunity;
group II corresponded to combined immunodeficiencies with
associated or syndromic features, group III was defined as
predominantly antibody deficiencies.
Sample Analysis
Peripheral blood samples were taken by venipuncture during
morning hours, aliquoted and sent for complete blood count,
flow cytometry, immunoglobulin (IgA, IgG), and TREC/KREC
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analysis. All blood samples were EDTA-anticoagulated and
analyzed on the day of collection to avoid cellular death.
Immunoglobulin levels were measured in blood serum.
Sample analysis was performed as described elsewhere (18). In
brief, three-four color flow cytometric immunophenotyping with
directly labeled monoclonal antibodies was used to determine
the following immune cell subsets: CD3-CD19+, CD3-CD(16 +
56)+, CD3+CD4+, and CD3+CD8+ following manufacturer’s
protocol. Further analysis was performed with a FACS Canto
II flow cytometer using FACSDiva v7.0 software (Becton
Dickinson). The total leucocyte count and differential was
measured with Advia 2120i hematology analyzer (Siemens). The
absolute size of each lymphocyte subpopulation was calculated
by multiplying the relative size of the lymphocyte subpopulation
by the absolute lymphocyte count. Immunoglobulin levels
were assessed using a biochemical analyzer Architect C8000
(Abbott, USA, Abbott kits) in accordance with manufacturers’
protocol. TREC and KREC assays were performed using real-
time PCR with fluorescent hybridization probes and reagents
for TREC/KREC assays: T&B PCR kit (ABV-test, Russia) (20),
in whole blood. The TREC/KREC levels were assayed in whole
blood samples as described previously (16, 18, 20), In brief, DNA
was extracted from 100 µl EDTA anticoagulated whole blood
by using RIBO-prep nucleic acid extraction kit (Amplisense R©,
Russia). The Real-time qPCR was performed using CFX 96
Real-Time PCR System (Bio Rad, USA). Amplification of ALB
was used to assess correct sampling and quality of DNA
extraction, as well as to determine TREC and KREC levels. The
number of TREC/KREC copies was calculated per 105 white
blood cells, accounting for the quantity of ALB using the formula:
[The number of TREC/KREC copies/the number of ALB copies]
× 200,000. The normal/cutoff levels of TRECs and KRECs of
1,000 copies/105 cells were used.
Statistical Analysis
Shapiro-Wilk test was used to assess whether analyzed variables
were normally distributed. Since the null hypothesis was not
rejected, Spearmen correlation coefficient was used to assess the
strength of the correlation between the variables. Sensitivity,
specificity and their 95% confidence intervals were computed
with stratified bootstrap replicates (21). Area under Receiver
Operating Characteristic (ROC)—curve (AUC) calculation was
followed by 95% confidence interval as suggested by DeLong
et al. (22). The diagnostic accuracy measures used were:
sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV). TREC/KREC accuracy in
diagnosing group I/II and group III PIDs were assessed. The
ROC-analysis was performed separately for PID groups I/II and
TABLE 1 | Characteristics of study participants.
PID Group Total number of patients Clinical diagnosis
(number of patients)
Age Gender
Male Female
Group I
(“Combined PID”)
Immunodeficiencies
affecting cellular and
humoral immunity
17 D81 Combined immunodeficiencies (17) 0–12 months
1–6 years
6–12 years
12–18 years
9
2
1
0
5
0
0
0
Group II
(“Syndromic PID”)
CID with associated or
syndromic features
80 D82 Immunodeficiency associated with other
major defects (13)
D82.1 Di George syndrome (39)
D82.4 Hyperimmunoglobulin E syndrome (5)
D84.8 Other specified immunodeficiencies (15)
G11.3 (8)
0–12 months
1–6 years
6–12 years
12–18 years
7
26
10
4
9
17
6
3
Group III
(“Antibody PID”)
Predominantly antibody
deficiencies
148 D80.0 Immunodeficiency with predominantly
antibody defects (4)
D80.1 Non-familial hypogammaglobulinaemia
(47)
D80.2 Selective deficiency of immunoglobulin A
(34)
D80.3 Selective deficiency of immunoglobulin G
(24)
D80.4 Selective deficiency of immunoglobulin M
(1)
D80.5 Immunodeficiency with increased
immunoglobulin M (4)
D83 Common variable immunodeficiency (34)
0–12 months
1–6 years
6–12 years
12–18 years
6
21
28
38
2
17
21
13
Control group (Healthy
children)
226 No clinical diagnosis of PID 0–12 months
1–6 years
6–12 years
12–18 years
9
41
36
25
5
48
33
29
All codes and diagnoses are in accordance with international classification of diseases, 10th revision (ICD-10).
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PID group III. The performance characteristics of all lymphocyte
subpopulations as well as combinations of TREC and KREC
were evaluated and compared in terms of (a) the sensitivity
(proportion detected of those with PID) at a fixed specificity
(proportion of controls correctly detected not to have PID)
and (b) AUC.
Due to TREC levels decreasing with age, every TREC
measurement was divided by the corresponding TREC reference
interval for the patient’s age group prior to analysis.
Results were considered statistically significant if p-value was
smaller than 0.05. All calculations were done using R package
version 3.4.1.
RESULTS
Study Population
The data was extracted from clinical notes and the laboratory
database of Speransky Children’s Hospital. Out of 3,055 patients
requiring flow cytometry within the given period of time, due
to financial restrictions (those eligible for flow cytometry to
be covered by compulsory health insurance in accordance to
local regulations. Regulations did not change throughout the
study period.), a total of 839 samples were analyzed using flow
cytometry and TREC assay and 931 samples were analyzed using
flow cytometry and KREC assay. Data on confirmed clinical
diagnosis was available from 471 participants. All data points
required for TREC/KREC diagnostic properties assessment were
available from 434 children and were included in the statistical
analysis. Out of 434 children with a doctor’s confirmed diagnosis,
189 were immunologically healthy, 97 were group I and II PID
patients and 148 were group III PID patients. The following
conditions were diagnosed in each subcategory in accordance
to International Classification of Diseases, 10th revision (ICD-
10) and classified following IUIS Phenotypic Classification
for Primary Immunodeficiencies (19): group I (combined
immunodeficiencies), group II (immunodeficiency associated
with other major defects, ataxia telangiectasia and other
specified immunodeficiencies), group III (immunodeficiency
FIGURE 1 | Patterns of change in TREC and KREC log-transformed (natural logarithm) levels in healthy individuals and PID patients at different age. Red dot
represents minimal normal level for a given age group.
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FIGURE 2 | Receiver operating characteristic (ROC) curves for each of
lymphocyte subpopulations (CD3, CD4, CD8, and CD19) individually;
combined diagnostic ability of all lymphocyte subpopulations and diagnostic
ability of TREC and KREC combination in “Combined PID” and “Syndromic
PID” diagnosis. Healthy individuals (n = 172); children diagnosed with
“Combined PID” and “Syndromic PID” (n = 60). AUC for TREC and a
combination of TREC and KREC = 0.82 (95% CI = 0.75–0.90).
with predominantly antibody defects and common variable
immunodeficiency). For the sake of the readers’ convenience we
will use the following terminology in the following sections of the
manuscript: “Combined PID” for group I, “Syndromic PID” for
group II and “Antibody PID” for group III. The diagnoses were
reached using clinical signs and immune phenotype. Genetic
testing was not available at the recruitment site.
All the samples were analyzed using flow cytometry,
turbidimetry, and TREC/KREC assays and were included into
the primary analysis of this study. Demographic data of the
participants is presented in Table 1.
Descriptive Results of Flow Cytometry and
TREC/KREC Testing
Levels of TREC decreased with age in healthy children, while
this was less evident in “Combined PID” and “Syndromic
PID.” Overall TREC levels were lower in “Combined PID” and
“Syndromic PID” compared to healthy individuals (Figure 1).
TREC/KREC Diagnostic Accuracy
The area under the curve for lymphocyte subpopulations (CD
3, 4, 8, and 19), immunoglobulins (IgA, IgG) and TREC/KREC
levels were assessed. Separate analyses were undertaken
for “Combined PID” and “Syndromic PID” (Figure 2) and
“Antibody PID” (Figure 3). The same analysis was performed to
assess ability of TREC/KREC to differentiate between “Combined
PID,” “Syndromic PID,” and “Antibody PID.”
FIGURE 3 | Receiver operating characteristic (ROC) curves for each of
lymphocyte subpopulations (CD3, CD4, CD8, and CD19) individually;
combined diagnostic ability of all lymphocyte subpopulations; IgA and IgG
combined; TREC and KREC combined and diagnostic ability of TREC, KREC,
IgA, and IgG combination in “Antibody PID” diagnosis. Healthy individuals (n =
144); children diagnosed with “Antibody PID” (n = 120). IgA, IgG, TREC, and
KREC AUC = 0.77 (95% CI = 0.71–0.82).
TABLE 2 | Diagnostic accuracy measures for different cutoff points of the
predicted probabilities for TREC in “Combined PID” and “Syndromic PID”
diagnosis.
Cutoff point
(probability)
PPV (%) NPV (%) Sensitivity (%) Specificity
(%)
Youden
index
0.05 28 92 97 13 9.5
0.1 29 90 93 21 14.2
0.15 32 90 90 32 22
0.2 33 89 85 41 25.7
0.25 37 88 78 54 31.8
0.3 46 90 78 67 45.7
0.35 59 89 72 83 54.3
0.4 75 88 65 92 57.4
Optimum cut-off point based on maximum value of the J index is presented in bold.
AUC for TREC and a combination of TREC and KREC for
“Combined PID” and “Syndromic PID” diagnosis was 0.82 (95%
CI = 0.75–0.90). As KREC did not add value to the model’s
predictive capacity, the data for TREC is presented (Table 2). The
cutoff point of a probability of 0.4 showed the best diagnostic
accuracy with regards to the sensitivity and specificity (65 and
92%), J = 57.4.
A combination of IgA, IgG, TREC and KREC demonstrated
the best AUC 0.77 (95% CI = 0.71–0.82) for “Antibody PID”
diagnosis but neither TREC or KREC nor combination of two
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TABLE 3 | Diagnostic accuracy measures for different cutoff points of the
predicted probabilities for a combination of TREC and KREC in “Antibody PID”
diagnosis.
Cutoff point
(probability)
PPV (%) NPV (%) Sensitivity (%) Specificity
(%)
Youden
index
0.35 46 75 98 4 2.5
0.4 46 64 93 11 3.6
0.45 47 56 61 42 2.5
0.5 57 56 14 91 5.2
0.55 42 54 4 95 0
0.6 50 55 2 99 0.3
Optimum cut-off point based on maximum value of the J index is presented in bold.
yielded good diagnostic ability (AUC 0.54, 95% CI = 0.47–0.61),
Table 3. TREC and KREC combination did not demonstrate any
added value to immunoglobulin level detection.
We then performed analysis to study ability of TREC/KREC
to differentiate between “Combined PID,” “Syndromic PID,”
and “Antibody PID.” As KREC did not add value to the
predictive model, the predictive model based on TREC levels is
presented (Figure 4). The AUC for TREC in “Combined PID”
and “Syndromic PID” diagnosis was 0.79 (95% CI = 0.70–0.87).
A cutoff point of a probability of 0.4 showed the best diagnostic
accuracy with regards to the sensitivity and specificity (66 and
84%; (Table 4), J = 50.2.
DISCUSSION
In this study, we tested the accuracy of TREC and KREC in
PID diagnosis. The models showed decent utility of TREC in
the diagnosis of “Combined PID” and “Syndromic PID.” To our
knowledge, this is the first attempt to use TREC/KREC not in
SCID screening but in PID diagnostics.
PID is a large group of disorders encompassing more than
400 conditions affecting development and/or functioning of the
immune system (23). Flow cytometry is a sensitive and important
tool in evaluating the immune system function and in PID
diagnosis (24). However, it is expensive, not easily available
in developing countries and requires appropriate training and
equipment. TREC and KREC may represent cheaper alternatives
and/or add value to PID diagnosis and screening. Low cost
methodology can be used in small laboratories and rural settings,
where complex and expensive tools are unavailable, to provide
access to primary PID evaluation.
Prior studies have noted the need in screening tool for early
SCID diagnosis, to reduce the risk of infections and organ
damage (6, 25). Early diagnosis is particularly important as lack
of early treatment is associated with severe complications and
increased mortality rates (26). TREC is a common screening
approach used for early SCID detection around the globe,
providing a good combination of sensitivity and specificity
(27, 28) with high cost-effectiveness (29). KREC’s role in early
screening is still debatable but some data suggest that it may
add value in certain cases (30). While TREC’s indispensability
in SCID screening is obvious, very little can be found in the
literature on the question of TREC/KREC use in other PID
FIGURE 4 | Receiver operating characteristic (ROC) curves for each of
lymphocyte subpopulations (CD3, CD4, CD8, and CD19) individually;
combined diagnostic ability of all lymphocyte subpopulations; IgA and IgG
combined; TREC and KREC combined and diagnostic ability of TREC, KREC,
IgA, and IgG combination in differentiating between “Combined PID” and
“Syndromic PID” and “Antibody PID.” “Combined PID” and “Syndromic PID”
individuals (n = 53); children diagnosed with “Antibody PID” (n = 120). TREC
AUC = 0.79 (95% CI = 0.70–0.87).
TABLE 4 | Differential diagnosis for “combined PID” and “syndromic PID” and
“antibody PID.” Accuracy measures for different cutoff points of the predicted
probabilities for TREC.
Cutoff point
(probability)
PPV (%) NPV (%) Sensitivity (%) Specificity
(%)
Youden
index
0.05 31 80 96 7 2.9
0.1 33 89 96 13 9.5
0.15 34 88 94 18 12.6
0.2 36 89 93 28 20
0.25 38 88 89 35 23.7
0.3 40 84 79 47 25.9
0.35 51 86 76 68 43.8
0.4 65 85 66 84 50.2
Optimum cut-off point based on maximum value of the J index is presented in bold.
diagnosis or their use as a screening tool (31–33). Previous
attempts to this end have predominantly focused on Common
Variable Immunodeficiency (CVID).
We hypothesized, that TREC and KREC may be adopted as a
surrogate method of PID diagnosis. Our models demonstrated
good AUCs indicating the potential of TREC to be used as
an additional tool in PID diagnosis. Our data show that when
TREC is used for differentiation between “Combined PID” and
“Syndromic PID” patients and healthy individuals, the cut-off
point probability of 0.4 provides high specificity (92%) with
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acceptable sensitivity (65%), further supporting our hypothesis
that use of TREC may have its place in PID diagnosis. TREC
may serve as an addition to existing tests and may be used as
a prerequisite to flow cytometry. We did not use any clinical
questionnaires in this study but expect that laboratory findings
combined with additional clinical data using standardized
instruments may facilitate development of a stronger diagnostic
model, improving utility.
TREC and KREC whether individually or combined, did
not show good diagnostic ability in diagnosing “Antibody
PID.” However, this result was expected, with immunoglobulin
measurement having the primary role in aiding the diagnosis.
Our further analysis highlights potential for TREC level
assessment in discrimination between “Combined PID,”
“Syndromic PID,” and “Antibody PID.” When a cut-off of
0.4-point probability was used, TREC reached specificity
of 84%. At present, the wide variety and lack of specificity
of PID clinical manifestations, do not allow physicians to
determine the exact area of immune defect during initial clinical
examination. Thus, the extensiveness of the primary laboratory
examination in a patient with suspected PID is often determined
by subjective clinical criteria, based on physician expertise.
Laboratory tests normally used vary from immunoglobulin
level assessment to assessment of a wide range of lymphocyte
subpopulations. There are no predefined universal guidelines
on how detailed the laboratory analysis should be, while
selection of diagnostic tests depends on the given clinical settings
and clinical immunologist. Normally, if initial tests reveal
deviations in humoral immunity the next logical step is cellular
immunity assessment to exclude combined immunodeficiency
and diagnose “Antibody PID.” Our data suggests that TREC
appears to be a useful additional tool to aid in the differentiation
between combined immunodeficiency and antibody deficiencies,
particularly in the settings with limited access to flow cytometry.
The qualitative method of TREC/KREC assessment is easy
and can be applied equally well to both whole blood and
Guthrie cards, as DNA extraction can be performed on either of
these samples.
A few diagnostic algorithms/approaches to children with
suspected PID were proposed. Among them excellent algorithm
from Dutch immunologist Esther DeVries’, based on a pattern
recognition approach and decision trees (34), and the Jeffrey
Modell Foundation’s 4 steps (35). We do not propose changes
to existing clinical approaches in routine PID diagnosis and
fully acknowledge that TREC/KREC should not be used as
a replacement of flow cytometry. Addition of TREC/KREC
measurements to aforementioned clinical approaches,
nevertheless, may improve predictive capacity of the tools,
which is worth further investigation.
The main limitation of this study is related to the use of ICD-
10 classification for PID diagnosis. The same ICD-10 code may
sometimes include heterogenous group of immunodeficiencies.
Genetic testing would be a preferable option; however, this
was not available for most of the patients due to economical
restrictions. Another limitation is the lack of Guthrie card use
in our study with all samples analyzed using whole blood,
which does not allow for a result extrapolation. No difference
is expected, however, between DNA extraction from the whole
blood sample and dried blood spot. Recruitment of patients of
three PID groups only, may also be considered a limitation,
even though it is unlikely to have influenced the outcomes
of this study. We acknowledge that participants defined as
“immunologically healthy” in this study can be considered as
“healthy” to a high degree of certainty, but no information on
naive cells and memory cells were collected. It is clear, however,
that “immunologically healthy” participants in this study do
not belong to Group I (“Combined PID”). Our study would
also have benefited from assessment of TREC/KREC diagnostic
accuracy in patients with a particular subtype of PID [e.g., X-
linked agammaglobulinemia (XLA)], but it was not possible due
to restricted number of patients. This should be addressed in
future research.
In conclusion, we found evidence that TRECmay have a place
in aiding PID diagnosis. The models showed decent diagnostic
accuracy measures for TREC in diagnosing “Combined PID”
and “Syndromic PID”. Further investigations in a larger cohort
in combination with addition of genetic diagnoses and/or
questionnaires focused on clinical symptoms are needed to
improve diagnostic performance and to further evaluate TREC
potential on a wider scale. It is too premature to draw definitive
conclusions, but with a few diagnostic algorithms available
(e.g., Esther DeVries’ and Jeffrey Modell Foundation’s 4 steps),
addition of TREC to such algorithms may allow for an improved
predictive ability. We would like to stress that TREC-based
PID diagnosis may be particularly important in the recourse-
limited countries and further research will benefit children in
these settings.
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